The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis

BACKGROUND: Prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (DAs) are generally the first-line treatment for them. Several studies have reviewed the recurrent rate of hyperprolactinemia after DAs withdrawal. However, few of them have concerned the recurrence risk of prol...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yunzhi, Li, Depei, Gu, Jiayu, Chen, Siyu, Wen, Xia, Dong, Jiajun, Jiang, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590353/
https://www.ncbi.nlm.nih.gov/pubmed/34774043
http://dx.doi.org/10.1186/s12902-021-00889-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590353/
https://www.ncbi.nlm.nih.gov/pubmed/34774043
http://dx.doi.org/10.1186/s12902-021-00889-1

Ejemplares similares